Research & Clinical Trials : Trials

Trials

Visit the U Health clinical trial website for information on all active trials in the U Health system.

Below is a list of all our current trials:

Enrollment Status Study Title Phase Contact CT.GOV identifier
Active, Enrolling ACESO: A Phase I/II, Randomized, Pilot trial to evaluate the Safety and Efficacy of Allogeneic Mesenchymal Human Stem Cells infusion therapy for Endothelial DySfunctiOn in diabetic subjects. I/II ISCI Study Info: 305-243-7444 NCT02886884
Active, Enrolling ANU: Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression I Andrew Kimmel 305-243-5510 NCT02675556
Active, Enrolling CRATUS: A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients with Aging Frailty. I/II ISCI Study Info: 305-243-7444 NCT02065245
Active, Enrolling ELPIS: Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients with Hypoplastic Left Heart Syndrome. I ISCI Study Info: 305-243-7444 NCT02398604
Active, Enrolling Hyperion: A Comparative study of subjects tHree to nine Years Past thEiR fInal follow-ON Study visit. N/A ISCI Study Info: 305-243-7444 N/A
Enrollment Complete Aether: A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients with Idiopathic Pulmonary Fibrosis. I Marilyn Glassberg 305-243-7888 NCT02013700
Enrollment Complete POSEIDON DCM: A Phase I/II Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Nonischemic Dilated Cardiomyopathy. I/II ISCI Study Info: 305-243-7444 NCT01392625
Enrollment Complete POSEIDON: A Phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cells versus allogeneic mesenchymal stem cells in patients with chronic ischemic left ventricular dysfunction secondary to myocardial infraction. The precutaneous stem cell injection delivery effects on neomyogenesis Pilot study. I/II ISCI Study Info: 305-243-7444 NCT01087996
Enrollment Complete PROMETHEUS: A phase I/II, randomized, double-blinded, placebo-controlled study of the safety and efficacy of intramyocardial injection of autologous human mesenchymal stem cells (MSCs) in patients with chronic ischemic left ventricular dysfunction secondary to myocardial infraction (MI) undergoing cardiac surgery for coronary artery bypass grafting (CABG). I/II ISCI Study Info: 305-243-7444 NCT00587990
Enrollment Complete TAC-HFT: A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Bone Marrow or Mesenchymal) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial. I/II ISCI Study Info: 305-243-7444 NCT00768066
Enrollment Complete TRIDENT: A phase II Randomized, Blinded Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Mesenchymal Stem Cells in Patients with Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction. II ISCI Study Info: 305-243-7444 NCT02013674
Not Yet Recruiting GALENE: A Phase I, Pilot Trial to evaluate the Safety and Efficacy of Injection of Allogeneic Mesenchymal Bone-Marrow Derived Human Stem Cells in Patients With Fistulizing Crohn’s Disease. I Diana Morillo (305) 243 – 6405 or (305) 243 – 8644 NCT02677350
Not Yet Recruiting POSEIDON II: A Phase II, Randomized-Blind Study Testing the Efficacy of Transendocardial Injection of Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy. II ISCI Study Info: 305-243-7444 N/A
Not Yet Recruiting SIRONA: A Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Patients with Metabolic Syndrome 2b ISCI Study Info: 305-243-7444 NCT02587572
Not Yet Recruiting TAC-HFT II: Phase I/II Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC and Cardiac Stem Cells) in Patients with Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infraction. I/II ISCI Study Info: 305-243-7444 NCT02503280
Multi-Center Clinical Trials
Enrollment Status Study Title Phase Contact CT.GOV identifier
Active, Enrolling CONCERT-HF: A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, and Efficacy of Autologous Mesenchymal Stem Cells and c-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects with Ischemic Heart Failure II ISCI Study Info: 305-243-7444 NCT02501811
Active, Enrolling SENECA: A Phase I, First-in-Human, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors with Anthracycline-Induced Cardiomyopathy I ISCI Study Info: 305-243-7444 NCT02509156
Enrollment Complete PACE: Clinical and MR Imaging Assessments in Patients with Intermittent Claudication following Injection of Bone Marrow Derived ALDH Bright Cells. N/A ISCI Study Info: 305-243-7444 NCT01774097
Enrollment Complete Vericel: 55-1202-1: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of Transendocardial Injection of Ixmyelocel-T in Subjects with Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) 2b ISCI Study Info: 305-243-7444 NCT01670981
Enrollment Complete CELLADON: A Phase 2/3, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure. 2b ISCI Study Info: 305-243-7444 NCT02346422

For more information about our ISCI clinical trials, please contact our Research Office at 305-243-7444.